{'fraction_non_alphanumeric': 0.016352201257861635, 'fraction_numerical': 0.005031446540880503, 'mean_word_length': 5.170542635658915, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The transition in practice: policy makers and purchasers.

The transition to CFC-free pressurised metered dose inhalers (pMDIs) is not optional and cannot be ignored. The UK Government intends that CFCs will be removed from all medicinal products by the end of 1999. An overall strategy is needed to guide health professionals and patients through the transition process. Collaborative working between the pharmaceutical industry, health authorities and relevant health professionals is essential to ensure a smooth transition with minimal disruption to patients. The factors that need to be taken into consideration for a smooth transition and the role of national and local drivers in this process are outlined. The main focus around change must be on patients' confidence in their medication.